One Backbone Multiple Viral Assets
Programmable PNA-Peptide Therapeutics for Rapid Antiviral Development
VIRITIS at a glance
Viritis is developing a programmable antiviral platform based on PNA-peptide therapeutics targeting conserved viral RNA sequences.
- AI-driven antiviral drug discovery platform
- Proprietary antisense molecular technology
- 97.1% cellular protection in proof-of-concept studies
- Rapid development of targeted antiviral candidates
- Designed to address emerging viral threats
Emerging viruses are evolving faster than drug development
Development of antiviral therapeutics traditionally takes many years. Meanwhile, new viral pathogens can emerge and spread globally within months.
Major challenges in antiviral drug development:
• Long discovery and development timelines
• Viral mutation and resistance
• Limited ability to rapidly respond to new pathogens
• Complex manufacturing and distribution requirements
The COVID-19 pandemic demonstrated the urgent need for rapid and adaptable antiviral therapeutic platforms.
A new age of antiviral therapies: EXHAUVIR
Key Advantages Of The Platform
From Sequence to treatment
Finding conserved genomic sequence in the targeted virus
Customizing our molecule (EXHAUVIR)
EXHUAVIR enter the cells then attached to the target virus
Cellular mechanisms destroy the virus
EXHUVIR is completely disintegrated without harmfull residue
In-vitro studies
Conducted on 5 human cell lines.
Key results:
• 97.1% cellular protection in cellular assays
• Targeting of conserved viral sequences
• Efficient disruption of viral replication
These results support Viritis platform potential for rapid therapeutic generation.
Market opportunity
The global antiviral therapeutics market represents a multi-billion-dollar opportunity
- Increasing emergence of viral diseases
- Global pandemic preparedness programs
- Rising viral resistance to existing treatments
- Increased investment in antiviral drugs
Platform-based antiviral technologies will play a key role in future global health challenges.
Antiviral pipeline
Managing team
Amit Turman
CEO
Technological entrepreneur with 12 years of experience leading startups from ideation to fundraising. Amit brings expertise in growth strategy, capital raising, and cross-functional team leadership.
DR Amit Philosoph
CTO
Molecular geneticist with 20 years of expertise in molecular virology, ASO’S (PNA), genetic engineering, bioinformatics, and biotechnology innovation.
Aaron Wistouch
Chairman
A former Israeli Treasury manager with experience in two major financial exits. He brings expertise in capital markets, financial management, and business development.
Dr. Emiliano Cohen
Head of AI
Expert in AI-driven genomics and bioinformatics with 15+ years of experience in genomic data analysis, target identification, and clinical exome interpretation.
